ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

Issues in Oncology

Cost of Care

Charles L. Bennett, MD, PhD, MPP and James O. Armitage, MD

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Charles L. Bennett, MD, PhD, MPP of the University of South Carolina College of Pharmacy, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss the emerging and future benefits of biosimilars.

Breast Cancer

Maura N. Dickler, MD and Clifford A. Hudis, MD

Maura N. Dickler, MD, and Clifford A. Hudis, MD, on Results From the CALGB Alliance Trial on Hormone Receptor–Positive Advanced Breast Cancer

Clifford A. Hudis, MD, and Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, discuss adding bevacizumab to letrozole as a first-line endocrine therapy for treatment of hormone receptor–positive advanced breast cancer (Abstract 501).

Breast Cancer

Richard G. Margolese, MD

Richard G. Margolese, MD, Summarizes NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Richard G. Margolese, MD, of McGill University discusses the improvement in breast cancer-free interval with anastrozole vs tamoxifen in patients with DCIS undergoing lumpectomy plus radiotherapy (Abstract LBA500).

Lymphoma

Laurie H. Sehn, MD, MPH, and James O. Armitage, MD

Laurie H. Sehn, MD, MPH, and James O. Armitage, MD, on Results of the GADOLIN Trial on Indolent Non-Hodgkin Lymphoma

James O. Armitage, MD, of the University of Nebraska Medical Center, and Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discuss a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

Oct

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Maura N. Dickler, MD, and Clifford A. Hudis, MD, on Results From the CALGB Alliance Trial on Hormone Receptor–Positive Advanced Breast Cancer

Richard G. Margolese, MD, Summarizes NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Laurie H. Sehn, MD, MPH, and James O. Armitage, MD, on Results of the GADOLIN Trial on Indolent Non-Hodgkin Lymphoma

Insurance and Cost Barriers to Oral Therapies for Blood Cancers

Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer

Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes

The Wistar Institute Names New President and Chief Executive Officer

Early Research Links Abdominal Obesity to Increased Lung Cancer Risk